

Cezar A Iliescu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6614889/publications.pdf>

Version: 2024-02-01

118
papers

2,658
citations

218381

26
h-index

214527

47
g-index

121
all docs

121
docs citations

121
times ranked

2773
citing authors

#	ARTICLE	IF	CITATIONS
1	Vascular Toxicities of Cancer Therapies. <i>Circulation</i> , 2016, 133, 1272-1289.	1.6	270
2	Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment. <i>Journal of the American Heart Association</i> , 2020, 9, e013757.	1.6	240
3	Cardiovascular Health of Patients With Cancer and Cancer Survivors. <i>Journal of the American College of Cardiology</i> , 2015, 65, 2739-2746.	1.2	198
4	SCAI Expert consensus statement: Evaluation, management, and special considerations of cardiovascular oncology patients in the cardiac catheterization laboratory (endorsed by the cardiological) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50</i>	0.7	152
5	Cardiovascular Interventions, 2016, 87, E202-23. SCAI expert consensus statement: Evaluation, management, and special considerations of cardiovascular oncology patients in the cardiac catheterization laboratory (Endorsed by the Cardiological) <i>Tj ETQq1 1 0.784314 rgBT /Overlock</i>	0.7	118
6	Cardiovascular Interventions, 2016, 87, 895-899.		
6	Percutaneous coronary intervention in cancer patients: a report of the prevalence and outcomes in the United States. <i>European Heart Journal</i> , 2019, 40, 1790-1800.	1.0	115
7	Outcomes of Cancer Patients Undergoing Percutaneous Pericardiocentesis for Pericardial Effusion. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1119-1128.	1.2	93
8	Cancer as a Risk Factor for Cardiovascular Disease. <i>Current Oncology Reports</i> , 2017, 19, 39.	1.8	60
9	Evaluation and Management of Cardiac Tumors. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2018, 20, 29.	0.4	58
10	Carcinoid heart disease. <i>Heart</i> , 2017, 103, 1488-1495.	1.2	56
11	Arterial Thrombosis in Patients with Cancer. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2018, 20, 40.	0.4	56
12	Immune checkpoint inhibitor myocarditis: elucidating the spectrum of disease through endomyocardial biopsy. <i>European Journal of Heart Failure</i> , 2021, 23, 1725-1735.	2.9	51
13	Stress-Induced Cardiomyopathy in Cancer Patients. <i>American Journal of Cardiology</i> , 2017, 120, 2284-2288.	0.7	50
14	Progressive and Reversible Conduction Disease With Checkpoint Inhibitors. <i>Canadian Journal of Cardiology</i> , 2017, 33, 1335.e13-1335.e15.	0.8	46
15	Targeted Cancer Therapies With Pericardial Effusions Requiring Pericardiocentesis Focusing on Immune Checkpoint Inhibitors. <i>American Journal of Cardiology</i> , 2019, 123, 1351-1357.	0.7	41
16	Role of cardiovascular imaging for the diagnosis and prognosis of cardiac amyloidosis. <i>Open Heart</i> , 2018, 5, e000881.	0.9	38
17	Safety of Diagnostic and Therapeutic Cardiac Catheterization in Cancer Patients With Acute Coronary Syndrome and Chronic Thrombocytopenia. <i>American Journal of Cardiology</i> , 2018, 122, 1465-1470.	0.7	36
18	Antiplatelet therapy and percutaneous coronary intervention in patients with acute coronary syndrome and thrombocytopenia. <i>Texas Heart Institute Journal</i> , 2010, 37, 336-40.	0.1	36

#	ARTICLE	IF	CITATIONS
19	Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 202-212.	0.8	34
20	Incidence, Predictors, and Impact on Survival of Left Ventricular Systolic Dysfunction and Recovery in Advanced Cancer Patients. <i>American Journal of Cardiology</i> , 2014, 113, 1893-1898.	0.7	33
21	Takotsubo Stress Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2016, 68, 1143-1144.	1.2	31
22	Chemotherapeutic Agents and the Risk of Ischemia and Arterial Thrombosis. <i>Current Atherosclerosis Reports</i> , 2018, 20, 10.	2.0	31
23	Immunomodulatory treatment of immune checkpoint inhibitor-induced myocarditis: Pathway toward precision-based therapy. <i>Cardiovascular Pathology</i> , 2020, 47, 107211.	0.7	31
24	Coronary Artery Dose-Volume Parameters Predict Risk of Calcification After Radiation Therapy. <i>Journal of Cardiovascular Imaging</i> , 2019, 27, 268.	0.2	30
25	Cardiovascular interventions in thrombocytopenic cancer patients. <i>Texas Heart Institute Journal</i> , 2011, 38, 259-60.	0.1	30
26	Radiation Toxicity to the Cardiovascular System. <i>Current Oncology Reports</i> , 2016, 18, 15.	1.8	28
27	“Bringing on the light” in a complex clinical scenario: Optical coherence tomography-guided discontinuation of antiplatelet therapy in cancer patients with coronary artery disease (PROTECT-OCT) <i>TJ ETQq1 1 0.784314 28 BT /Ov</i>	0.7	28
28	Radiation-Induced Vascular Disease—A State-of-the-Art Review. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 652761.	1.1	28
29	Acute Coronary Syndrome Management in Cancer Patients. <i>Current Oncology Reports</i> , 2018, 20, 78.	1.8	27
30	Cardiovascular manifestations of Erdheim-Chester disease. <i>Echocardiography</i> , 2019, 36, 229-236.	0.3	24
31	An update on the management and outcomes of cancer patients with severe aortic stenosis. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 94, 438-445.	0.7	22
32	Percutaneous coronary intervention and in-hospital outcomes in patients with leukemia: a nationwide analysis. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 53-63.	0.7	20
33	Machine Learning-Augmented Propensity Score Analysis of Percutaneous Coronary Intervention in Over 30 Million Cancer and Non-cancer Patients. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 620857.	1.1	20
34	Radiation-related heart and vascular disease. <i>Future Oncology</i> , 2015, 11, 2067-2076.	1.1	18
35	Management of CAD in Patients with Active Cancer: the Interventional Cardiologists’ Perspective. <i>Current Cardiology Reports</i> , 2017, 19, 56.	1.3	18
36	Differentiation of Cardiac Masses by Cardiac Magnetic Resonance Imaging. <i>Current Cardiovascular Imaging Reports</i> , 2020, 13, 1.	0.4	18

#	ARTICLE	IF	CITATIONS
37	Fulminant Vascular and Cardiac Toxicity Associated with Tyrosine Kinase Inhibitor Sorafenib. <i>Cardiovascular Toxicology</i> , 2019, 19, 382-387.	1.1	17
38	Cardiac toxicities of anticancer treatments. <i>Current Opinion in Cardiology</i> , 2019, 34, 441-450.	0.8	16
39	Acute myocardial infarction in a high-risk cancer population: Outcomes following conservative versus invasive management. <i>International Journal of Cardiology</i> , 2020, 313, 1-8.	0.8	16
40	Percutaneous Coronary Intervention and Outcomes in Patients With Lymphoma in the United States (Nationwide Inpatient Sample [NIS] Analysis). <i>American Journal of Cardiology</i> , 2019, 124, 1190-1197.	0.7	15
41	Multimodality imaging in carcinoid heart disease. <i>Open Heart</i> , 2019, 6, e001060.	0.9	15
42	Applications of Cardiac Computed Tomography in the Cardio-Oncology Population. <i>Current Treatment Options in Oncology</i> , 2019, 20, 47.	1.3	15
43	Clinical outcomes of percutaneous mitral valve repair with MitraClip for the management of functional mitral regurgitation. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 94, 820-826.	0.7	15
44	Resolution of Myelofibrosis-Associated Pulmonary Arterial Hypertension following Allogeneic Hematopoietic Stem Cell Transplantation. <i>Pulmonary Circulation</i> , 2016, 6, 611-613.	0.8	14
45	Echocardiography and Fluoroscopy-Guided Pericardiocentesis for Cancer Patients With Cardiac Tamponade and Thrombocytopenia. <i>Journal of the American College of Cardiology</i> , 2016, 68, 771-773.	1.2	14
46	The role of cardio-protective agents in cardio-preservation in breast cancer patients receiving Anthracyclines ± Trastuzumab: a Meta-analysis of clinical studies. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 153, 103006.	2.0	14
47	Effectiveness and safety of same day discharge after left atrial appendage closure under moderate conscious sedation. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, 912-916.	0.7	14
48	How to Diagnose and Manage QT Prolongation in Cancer Patients. <i>JACC: CardioOncology</i> , 2021, 3, 145-149.	1.7	14
49	Transcatheter closure of patent foramen ovale for secondary prevention of ischemic stroke: Quantitative synthesis of pooled randomized trial data. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 92, 1153-1160.	0.7	13
50	Interventional Cardio-Oncology: Adding a New Dimension to the Cardio-Oncology Field. <i>Frontiers in Cardiovascular Medicine</i> , 2018, 5, 48.	1.1	13
51	Ischemic Heart Disease: Special Considerations in Cardio-Oncology. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2017, 19, 37.	0.4	11
52	The Onco-cardiologist Dilemma: to Implant, to Defer, or to Avoid Transcatheter Aortic Valve Replacement in Cancer Patients with Aortic Stenosis?. <i>Current Cardiology Reports</i> , 2019, 21, 83.	1.3	11
53	Carcinoid Heart Disease: a Comprehensive Review. <i>Current Cardiology Reports</i> , 2019, 21, 140.	1.3	11
54	QT Prolongation in Cancer Patients. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 613625.	1.1	10

#	ARTICLE	IF	CITATIONS
55	Cardiovascular Complications of Chimeric Antigen Receptor T-Cell Therapy: The Cytokine Release Syndrome and Associated Arrhythmias. <i>Journal of Immunotherapy and Precision Oncology</i> , 2020, 3, 113-120.	0.6	10
56	Identifying Hemostatic Thresholds in Cancer Patients Undergoing Coronary Angiography Based on Platelet Count and Thromboelastography. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 9.	1.1	9
57	Prevalence of pulmonary hypertension in myelofibrosis. <i>Annals of Hematology</i> , 2020, 99, 781-789.	0.8	9
58	Management strategies and clinical outcomes of acute myocardial infarction in leukaemia patients: Nationwide insights from United States hospitalisations. <i>International Journal of Clinical Practice</i> , 2020, 74, e13476.	0.8	9
59	Immune Checkpoint Inhibitors (ICIs)-Related Cardiotoxicity. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1244, 277-285.	0.8	9
60	Stress cardiomyopathy in hospitalized patients with cancer: machine learning analysis by primary malignancy type. <i>ESC Heart Failure</i> , 2021, , .	1.4	9
61	Cardiac Magnetic Resonance Predicting Outcomes Among Patients at Risk for Cardiac AL Amyloidosis. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 626414.	1.1	8
62	TAVR in Cancer Patients: Comprehensive Review, Meta-Analysis, and Meta-Regression. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 641268.	1.1	8
63	Cancer treatment resumption in patients with new-generation drug-eluting stents. <i>Coronary Artery Disease</i> , 2021, 32, 295-301.	0.3	8
64	A Cancer Paradox: Machine-Learning Backed Propensity-Score Analysis of Coronary Angiography Findings in Cardio-Oncology. <i>Journal of Invasive Cardiology</i> , 2019, 31, 21-26.	0.4	8
65	TAVR and cancer: machine learning-augmented propensity score mortality and cost analysis in over 30 million patients. <i>Cardio-Oncology</i> , 2021, 7, 25.	0.8	7
66	Response by Herrmann et al to Letter Regarding Article, "Vascular Toxicities of Cancer Therapies: The Old and the New" An Evolving Avenue. <i>Circulation</i> , 2016, 134, e466-e467.	1.6	6
67	Refractory radiation-induced coronary artery disease: mapping the path and guiding treatment with optical coherence tomography. <i>International Journal of Cardiovascular Imaging</i> , 2019, 35, 759-760.	0.7	6
68	Opportunities for improved cardiovascular disease prevention in oncology patients. <i>Current Opinion in Cardiology</i> , 2020, 35, 531-537.	0.8	6
69	Lenalidomide-Induced Myocarditis, Rare But Possibly Fatal Toxicity of a Commonly Used Immunotherapy. <i>JACC: Case Reports</i> , 2020, 2, 2095-2100.	0.3	6
70	Transcatheter and surgical aortic valve replacement impact on outcomes and cancer treatment schedule. <i>International Journal of Cardiology</i> , 2021, 326, 62-70.	0.8	6
71	Cardiac Interventional Procedures in Cardio-Oncology Patients. <i>Cardiology Clinics</i> , 2019, 37, 469-486.	0.9	5
72	How to Perform Pericardiocentesis in Cancer Patients With Thrombocytopenia. <i>JACC: CardioOncology</i> , 2021, 3, 452-456.	1.7	5

#	ARTICLE	IF	CITATIONS
73	Acute coronary syndromes in cancer patients. <i>Journal of Cardiovascular Medicine</i> , 2020, 21, 944-952.	0.6	5
74	Managing Post-Pneumonectomy Tension Hydrothorax. <i>Annals of the American Thoracic Society</i> , 2017, 14, 1031-1035.	1.5	4
75	Association between ibrutinib and mid-cavitary Takotsubo cardiomyopathy: a case report and a review of chemotherapy-induced Takotsubo's cardiomyopathy. <i>European Heart Journal - Case Reports</i> , 2017, 1, ytx006.	0.3	4
76	The 1, 2, 3, 4 of carcinoid heart disease: Comprehensive cardiovascular imaging is the mainstay of complex surgical treatment (Review). <i>Oncology Letters</i> , 2019, 17, 4126-4132.	0.8	4
77	Coronary Lesions in Takayasu Arteritis With Chronic Myelogenous Leukemia—Intravascular Assessment With Optical Coherence Tomography and Fractional Flow Reserve. <i>Circulation Journal</i> , 2018, 83, 245-246.	0.7	4
78	Impact of Cardiopulmonary Resuscitation on Survival in Cancer Patients. <i>JACC: CardioOncology</i> , 2020, 2, 359-362.	1.7	4
79	Impact of cardiopulmonary resuscitation (CPR) on the survival of patients with cancer: DNR before or after cardiac arrest?. <i>Journal of Clinical Oncology</i> , 2018, 36, 71-71.	0.8	4
80	Acute coronary syndrome in patients with cancer. <i>Expert Review of Cardiovascular Therapy</i> , 2022, 20, 275-290.	0.6	4
81	The role of cardiac MRI in cardio-oncology. <i>Future Cardiology</i> , 2017, 13, 311-316.	0.5	3
82	State-of-the-art Review: Interventional Onco-Cardiology. Current Treatment Options in <i>Cardiovascular Medicine</i> , 2020, 22, 1.	0.4	3
83	Cardiac Toxicities Associated with Immune Checkpoints Inhibitors: Mechanisms, Manifestations and Management. <i>Korean Circulation Journal</i> , 2021, 51, 579.	0.7	3
84	Coronary Stent Healing in Cancer Patients—An Optical Coherence Tomography Perspective. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 665303.	1.1	3
85	Acute Coronary Syndrome, Thrombocytopenia, and Antiplatelet Therapy in Critically Ill Cancer Patients. , 2020, , 711-732.		3
86	The Role of Cardiovascular Imaging and Serum Biomarkers in Identifying Cardiotoxicity Related to Cancer Therapeutics. <i>Methodist DeBakey Cardiovascular Journal</i> , 2021, 15, 258.	0.5	3
87	Predictors of Recurrence and Survival in Cancer Patients With Pericardial Effusion Requiring Pericardiocentesis. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, .	1.1	3
88	Structural Transcatheter Cardiac Interventions in the Cardio-Oncology Population. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2021, 23, 1.	0.4	2
89	Rate of Progression of Aortic Stenosis in Patients With Cancer. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 644264.	1.1	2
90	Prognostic Factors and Overall Survival After Pericardiocentesis in Patients With Cancer and Thrombocytopenia. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 638943.	1.1	2

#	ARTICLE	IF	CITATIONS
91	Singleâ€access dualâ€injection technique (SADIT) for highâ€risk PCI with Impella CP. Catheterization and Cardiovascular Interventions, 2021, 98, 1138-1140.	0.7	2
92	Interventional Strategies in Cancer-induced Cardiovascular Disease. Current Oncology Reports, 2021, 23, 133.	1.8	2
93	Expression of T-cell populations and molecular markers of human myocardium with checkpoint-induced myocarditis.. Journal of Clinical Oncology, 2019, 37, 79-79.	0.8	2
94	Clinical Impact of Cardiovascular Magnetic Resonance in Cancer Patients With Suspected Cardiomyopathy. Frontiers in Cardiovascular Medicine, 2021, 8, 734820.	1.1	2
95	Immune Checkpoint Inhibitor (ICI)-Related Cardiotoxicity. Advances in Experimental Medicine and Biology, 2021, 1342, 377-387.	0.8	2
96	Percutaneous Coronary Intervention in Patients With Gynecological Cancer: Machine Learning-Augmented Propensity Score Mortality and Cost Analysis for 383,760 Patients. Frontiers in Cardiovascular Medicine, 2021, 8, 793877.	1.1	2
97	Editorial Commentary: Update on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicities. Trends in Cardiovascular Medicine, 2019, 29, 40.	2.3	1
98	Assessment of Vascular Patency and Inflammation with Intravascular Optical Coherence Tomography in Patients with Superficial Femoral Artery Disease Treated with Zilver PTX Stents. Cardiovascular Revascularization Medicine, 2020, 21, 101-107.	0.3	1
99	Clinical outcomes after fractional flow reserve-guided treatment of oncology patients.. Journal of Clinical Oncology, 2018, 36, e22106-e22106.	0.8	1
100	Impact of pericardial effusion for patients receiving immune checkpoint inhibitors.. Journal of Clinical Oncology, 2019, 37, e14121-e14121.	0.8	1
101	Myocardial Dysfunction in Patients with Cancer. Heart Failure Clinics, 2022, 18, 361-374.	1.0	1
102	Reclassification of Treatment Strategy with Fractional Flow Reserve in Cancer Patients with Coronary Artery Disease. Medicina (Lithuania), 2022, 58, 884.	0.8	1
103	Miscellaneous Syndromes (Takotsubo's, Orthostasis, and Differentiation Syndrome). , 2016, , 291-312.		0
104	Simultaneous Congenital Anomaly, Stenosis, and Compression. JACC: Cardiovascular Interventions, 2018, 11, 2537-2539.	1.1	0
105	Halloween in the Cath Lab: spider web pericardial effusion. European Heart Journal Cardiovascular Imaging, 2020, 21, 317.	0.5	0
106	Interventional Cardiology in the Cancer Patient. , 2019, , 1-20.		0
107	Acute Coronary Syndrome, Thrombocytopenia, and Antiplatelet Therapy in Critically Ill Cancer Patients. , 2019, , 1-23.		0
108	Skip Soft Definitions and Focus on Hardâ€Endpoints. JACC: CardioOncology, 2019, 1, 218-220.	1.7	0

#	ARTICLE	IF	CITATIONS
109	Percutaneous Muscular Ventricular Septal Defect Closure with 2D Transthoracic Echocardiography: Can We Sufficiently Visualize It?. Eurasian Journal of Medicine, 2021, 53, 144-147.	0.2	0
110	Manual Aspiration Thrombectomy for Embolic Acute Mesenteric Ischemia. Texas Heart Institute Journal, 2021, 48, .	0.1	0
111	Los confinamientos de la población por el Covid-19 pueden empeorar las desigualdades socioeconómicas que impactan de forma desproporcionada en las minorías raciales: rentabilidad aumentada por aprendizaje automático y análisis ético computacional. Medicina Y Etica: Revista Internacional De Bioetica, Deontologia Y Etica Medica, 2021, 32, 759-800.	0.1	0
112	Acute Coronary Syndrome in Patients with Cancer. , 2018, , 81-92.		0
113	Chronic thrombocytopenia in cancer patients: Impact on percutaneous coronary intervention and antiplatelet therapy.. Journal of Clinical Oncology, 2018, 36, e22092-e22092.	0.8	0
114	Effect of Pulmonary Hypertension and Other Cardiovascular Diseases in Overall Prognosis of Patients with Myelofibrosis. Blood, 2018, 132, 4310-4310.	0.6	0
115	Predictors of mortality following cardiac surgery for carcinoid heart disease.. Journal of Clinical Oncology, 2019, 37, e15692-e15692.	0.8	0
116	Interventional Cardiology in the Cancer Patient. , 2020, , 787-806.		0
117	The impact of therapeutic mediastinal radiation on stent healing in cancer patients: An optical coherence tomography study.. Journal of Clinical Oncology, 2020, 38, e19096-e19096.	0.8	0
118	Coronary intervention in cancer patients: the need for personalized cardiac care. Revista Romana De Cardiologie, 2020, 30, 389-398.	0.0	0